comprehens
data
serial
respiratori
viral
load
serum
antibodi
respons
patient
infect
sever
acut
respiratori
syndrom
coronaviru
yet
avail
nasopharyng
throat
swab
usual
obtain
serial
viral
load
monitor
respiratori
infect
gather
specimen
caus
discomfort
patient
put
healthcar
worker
risk
aim
ascertain
serial
respiratori
viral
load
posterior
oropharyng
deep
throat
saliva
sampl
patient
serum
antibodi
respons
method
cohort
studi
two
hospit
hong
kong
includ
patient
laboratoryconfirm
obtain
sampl
blood
urin
posterior
oropharyng
saliva
rectal
swab
serial
viral
load
ascertain
revers
transcriptas
quantit
pcr
rtqpcr
antibodi
level
intern
nucleoprotein
np
surfac
spike
protein
receptor
bind
domain
rbd
measur
use
eia
wholegenom
sequenc
done
identifi
possibl
mutat
aris
infect
find
jan
feb
patient
screen
inclus
includ
median
age
year
rang
median
viral
load
posterior
oropharyng
saliva
respiratori
specimen
present
log
copi
per
ml
iqr
salivari
viral
load
highest
first
week
symptom
onset
subsequ
declin
time
slope
ci
one
patient
viral
rna
detect
day
symptom
onset
older
age
correl
higher
viral
load
spearman
ci
patient
serum
sampl
avail
day
longer
symptom
onset
rate
seroposit
antinp
igg
antinp
igm
antirbd
igg
antirbd
igm
igg
level
correl
viru
neutralis
titr
genom
mutat
detect
serial
sampl
interpret
posterior
oropharyng
saliva
sampl
noninvas
specimen
accept
patient
healthcar
worker
unlik
sever
acut
respiratori
syndrom
patient
highest
viral
load
near
present
could
account
fastspread
natur
epidem
find
emphasis
import
stringent
infect
control
earli
use
potent
antivir
agent
alon
combin
highrisk
individu
serolog
assay
complement
rtqpcr
diagnosi
coronaviru
diseas
caus
sever
acut
respiratori
syndrom
coronaviru
first
report
china
decemb
although
middl
east
respiratori
syndrom
coronaviru
merscov
sever
acut
respiratori
syndrom
coronaviru
sarscov
infect
higher
mortal
rate
spread
much
rapidli
merscov
sarscov
reliabl
data
profil
serial
viral
load
serum
antibodi
respons
need
urgent
guid
antivir
treatment
infect
control
epidemiolog
measur
vaccin
peak
viral
load
patient
merscov
sarscov
infect
occur
around
day
symptom
onset
could
associa
ted
nosocomi
outbreak
involv
healthcar
worker
clinic
studi
antivir
agent
sar
show
viral
load
decreas
significantli
treatment
success
systemat
studi
two
import
variabl
statist
analysi
done
although
preliminari
descript
studi
report
studi
respiratori
viru
infect
serial
sampl
nasopharyng
throat
swab
use
viral
load
monitor
howev
collect
nasopharyng
throat
swab
specimen
induc
cough
sneez
gener
aerosol
potenti
health
hazard
healthcar
worker
collect
throat
swab
also
requir
direct
inspect
patient
posterior
pharynx
tonsil
furthermor
collect
nasopharyng
specimen
rel
invas
procedur
uncomfort
even
induc
bleed
patient
reluct
provid
sampl
account
pauciti
timepoint
viral
load
studi
respiratori
viru
infect
find
previou
studi
shown
high
concord
saliva
nasopharyng
aspir
specimen
laboratori
diagnosi
respi
ratori
virus
report
use
posterior
oro
pharyng
deep
throat
saliva
diagnosi
viral
load
monitor
cohort
patient
report
use
selfcollect
posterior
oro
pharyn
geal
saliva
sampl
patient
avoid
close
contact
healthcar
worker
patient
viral
load
monitor
also
monitor
serial
serum
antibodi
level
patient
includ
consecut
patient
laboratori
confirm
admit
princess
margaret
hospit
queen
mari
hospit
hong
kong
hong
kong
patient
test
base
clinic
epidemiolog
criteria
outlin
updat
hospit
author
initi
laboratori
confirm
done
use
nasopharyng
sputum
specimen
public
health
laboratori
centr
hong
kong
exclud
patient
archiv
saliva
serum
sampl
insuffici
test
studi
approv
institut
review
board
univers
hong
konghospit
author
hong
kong
west
cluster
uw
sinc
archiv
specimen
use
written
inform
consent
waiv
patient
includ
studi
report
previous
clinic
inform
viral
load
singl
copi
rnadepend
rna
polymerasehelicas
gene
antibodi
respons
viral
genom
analysi
report
viral
load
monitor
patient
ask
produc
earli
morn
saliva
sampl
posterior
oropharynx
ie
cough
clear
throat
toothbrush
breakfast
naso
pharyn
geal
secret
move
posteriorli
broncho
pulmonari
secret
move
ciliari
activ
posterior
oro
phar
yn
geal
area
patient
supin
posit
sleep
patient
instruct
supervis
nurs
viral
transport
medium
ad
saliva
specimen
patient
intub
obtain
endotrach
aspir
instead
posterior
oropharynx
saliva
initi
experi
show
saliva
sampl
promis
viral
load
monitor
patient
also
retriev
serum
remnant
blood
sampl
taken
routin
bio
chemic
test
refriger
sampl
antibodi
test
could
done
record
clinic
find
predesign
databas
includ
patient
histori
physic
examin
find
haematolog
biochem
radiolog
microbiolog
investig
defin
sever
diseas
need
supplement
oxygen
admiss
intens
care
unit
icu
death
evid
studi
search
pubm
feb
limit
start
date
term
coronaviru
antibodi
viral
load
restrict
search
articl
publish
english
search
retriev
report
clinic
progress
coronaviru
diseas
covid
respect
tempor
viral
load
concomit
serum
antibodi
profil
identifi
one
correspond
piec
viral
load
statist
analysi
anoth
articl
case
antibodi
respons
present
find
observ
cohort
studi
tempor
profil
viral
load
sever
acut
respiratori
syndrom
coronaviru
posterior
oropharyng
saliva
sampl
serum
antibodi
respons
date
symptom
onset
correl
clinic
find
salivari
viral
load
highest
first
week
symptom
onset
subsequ
declin
time
eia
igg
igm
intern
viral
nucleoprotein
np
surfac
spike
protein
receptor
bind
domain
rbd
show
correl
antibodi
respons
neutralis
antibodi
titr
posterior
oropharyng
saliva
specimen
noninvas
accept
patient
use
initi
diagnosi
subsequ
viral
load
monitor
earli
peak
viral
load
import
implic
transmiss
commun
hospit
set
eia
igg
igm
intern
viral
np
surfac
spike
protein
rbd
use
delay
present
retrospect
diagnosi
mild
case
posit
eia
antibodi
level
correl
well
neutralis
antibodi
titr
studi
role
immunopatholog
antivir
therapi
warrant
inhous
revers
transcriptas
quanti
tativ
pcr
rtqpcr
target
rnadependentrnapolymerasehelicas
gene
region
describ
appendix
p
eia
nucleo
protein
np
spike
protein
receptor
bind
domain
rbd
describ
modif
recombin
np
spike
protein
rbd
use
eia
assess
puriti
np
rbd
sodium
dodecyl
sulphat
polyacrylamid
gel
electro
phor
esi
western
blot
figur
b
appendix
pp
posit
sampl
includ
run
posit
control
use
archiv
anonym
sampl
neg
control
cutoff
seroposit
set
mean
valu
anonym
archiv
serum
specimen
plu
sd
verifi
valid
eia
competit
eia
appendix
p
western
blot
use
patient
serum
sampl
figur
appendix
p
microneutralis
assay
viru
cultur
describ
appendix
pp
wholegenom
sequenc
use
oxford
nanopor
minion
devic
oxford
nanopor
technolog
oxford
uk
describ
appendix
p
statist
analys
use
spss
version
prism
version
compar
categor
variabl
use
fisher
exact
test
continu
variabl
mannwhitney
u
test
use
spearman
correl
assess
relat
age
viral
load
p
valu
less
judg
statist
signific
funder
role
studi
design
data
collect
data
analysi
data
interpret
write
report
correspond
author
full
access
data
studi
final
respons
decis
submit
public
jan
feb
patient
screen
inclus
includ
male
ten
femal
ten
patient
sever
requir
oxygen
supplement
patient
mild
diseas
median
age
patient
year
rang
patient
chronic
medic
ill
common
lie
diseas
hypertens
six
patient
diabet
four
chronic
comorbid
common
among
patient
sever
seven
patient
sever
diseas
chronic
comorbid
vs
four
mild
diseas
although
differ
signific
tabl
five
patient
admit
icu
includ
three
requir
intub
two
patient
die
median
interv
symptom
onset
hospitalis
day
rang
present
common
symptom
fever
patient
follow
cough
five
chill
four
dyspnoea
four
tabl
dyspnoea
significantli
frequent
among
ten
patient
sever
diseas
among
mild
diseas
four
ten
vs
none
serum
alkalin
phosphatas
significantli
higher
among
patient
sever
diseas
among
mild
diseas
ul
rang
vs
ul
lymphocyt
count
lower
among
patient
sever
diseas
among
mild
diseas
cell
per
l
rang
vs
differ
signific
lymphopenia
neutrophilia
present
higher
proport
patient
sever
diseas
mild
diseas
differ
signific
respect
chest
radiograph
abnorm
seen
patient
multifoc
groundglass
lung
opac
seen
patient
ct
rna
detect
blood
sampl
five
patient
rectal
swab
four
detect
rate
sever
mild
case
differ
respect
tabl
rna
detect
urin
specimen
lopinavirritonavir
without
ribavirin
interferon
beta
given
patient
differ
timepoint
symptom
onset
total
respiratori
specimen
obtain
pati
ent
mean
respiratori
specimen
per
patient
median
viral
load
present
log
copi
per
ml
iqr
rna
detect
saliva
three
patient
specimen
undetect
viral
load
assign
valu
log
copi
per
ml
correl
note
day
symptom
onset
initi
viral
load
spearman
viral
load
posterior
oropharyng
saliva
sampl
highest
first
week
symptom
onset
gradual
declin
slope
ci
figur
endotrach
aspir
viral
load
avail
day
symptom
onset
show
nonsignific
declin
slope
ci
patient
surviv
seven
viral
rna
detect
day
longer
symptom
onset
associ
seen
prolong
detect
viral
rna
day
symptom
onset
sever
ill
one
patient
viral
rna
detect
day
symptom
onset
anoth
patient
undetect
viral
load
day
symptom
onset
rebound
viral
load
day
follow
day
undetect
viral
load
signific
posit
correl
age
peak
viral
load
note
spearman
ci
figur
median
initi
peak
viral
load
sever
case
log
higher
mild
case
although
differ
signific
figur
c
initi
peak
viral
load
differ
patient
without
comorbid
comorbid
figur
e
patient
viral
load
antibodi
result
avail
week
week
median
viral
load
log
copi
per
ml
rang
concomit
median
optic
densiti
od
antinp
igg
rang
week
wherea
week
median
viral
load
log
copi
per
ml
rang
concomit
median
od
antinp
igg
rang
serum
specimen
obtain
patient
mean
serum
specimen
per
patient
increas
note
igg
igm
antibodi
level
np
rbd
patient
day
later
symptom
assess
host
factor
affect
antibodi
titr
correl
analys
highest
od
valu
convalesc
period
third
week
symptom
onset
age
comorbid
patient
comorbid
lower
antirbd
igg
od
without
comorbid
although
differ
signific
median
od
vs
appendix
p
associ
seen
comorbid
antinp
igg
igm
od
valu
age
antinp
igm
igg
antirbd
igm
igg
od
valu
appendix
p
specimen
microneutralis
assay
titr
less
assign
valu
specimen
microneutralis
assay
titr
greater
assign
valu
one
patient
microneutralis
antibodi
assay
done
ten
serial
sampl
correl
micro
neutralis
assay
titr
antinp
igg
antirbd
igg
better
microneutralis
assay
titr
antinp
igm
antirbd
igm
figur
nanopor
sequenc
success
pair
sampl
four
patient
interv
first
second
specimen
day
viral
mutat
identifi
pair
sampl
individu
patient
analys
serial
viral
load
antibodi
kinet
viral
genom
patient
hong
kong
patient
viral
load
high
present
declin
steadili
despit
develop
ment
antibodi
surfac
intern
protein
viral
rna
could
still
detect
posterior
oropharyng
deep
throat
saliva
sampl
third
patient
day
longer
peak
viral
load
correl
posit
age
patient
antibodi
respons
day
later
onset
symptom
viral
wholegenom
sequenc
pair
sampl
four
patient
identifi
singl
nucleotid
poli
morphism
high
viral
load
present
record
cohort
even
patient
hospitalis
shortli
symptom
onset
use
nasal
swab
throat
swab
zou
colleagu
also
report
high
viral
load
shortli
symptom
onset
howev
studi
cycl
threshold
valu
exact
viral
load
report
statist
correl
analysi
done
clinic
variabl
age
comorbid
diseas
sever
antibodi
respons
viral
load
profil
similar
influenza
peak
around
time
symptom
onset
contrast
sarscov
around
day
merscov
second
week
symptom
onset
high
viral
load
present
suggest
transmit
easili
even
symptom
rel
mild
find
could
account
effici
persontoperson
transmiss
note
commun
healthcar
set
cluster
famili
workplac
religi
gather
food
premis
wide
report
viral
load
profil
import
guid
antivir
treatment
sinc
viral
load
alreadi
peak
around
time
hospit
admiss
risk
emerg
antivir
resist
could
similar
singledrug
treatment
influenza
adamantan
acid
polymeras
inhibitor
neuraminidas
inhibitor
howev
previou
clinic
trial
influenza
treatment
show
tripl
antivir
combin
could
significantli
improv
clinic
outcom
viral
load
profil
could
reduc
emerg
resist
viru
quasispeci
current
standard
treatment
avail
figur
relat
viral
load
age
diseas
sever
correl
age
peak
viral
load
comparison
initi
b
peak
c
viral
load
sever
mild
case
comparison
initi
peak
e
viral
load
patient
comorbid
without
comorbid
sarscov
infect
previou
treatment
studi
show
combin
lopinavirritonavir
ribavirin
led
significantli
fewer
compli
cation
eg
acut
respiratori
distress
syndrom
death
report
histor
control
treat
ribavirin
lopinavirritonavir
interferon
beta
also
reduc
lung
damag
decreas
viral
load
nonhuman
primat
model
merscov
lopinavir
proteas
inhibitor
invitro
activ
sarscov
merscov
howev
idea
sarscov
proteas
antivir
target
lopinavir
base
pure
bind
comput
model
proteas
inhibitor
nucleotid
analogu
eg
remdesivir
gilead
scienc
foster
citi
ca
usa
potenti
candid
treatment
combin
treatment
virustarget
hosttarget
agent
improv
clinic
outcom
investig
studi
sarscov
shown
high
initi
viral
load
associ
death
howev
studi
show
median
viral
load
log
higher
sever
case
mild
case
differ
signific
older
age
associ
higher
peak
viral
load
previou
studi
patient
infect
sarscov
older
age
independ
factor
associ
higher
viral
load
expect
immunosenesc
impair
innat
adapt
immun
respons
rna
could
detect
day
longer
third
patient
surviv
cohort
one
patient
rna
detect
day
prolong
detect
viral
rna
day
longer
also
commonli
seen
patient
merscov
sarscov
infect
prolong
detect
viral
rna
repres
challeng
limit
avail
hospit
isol
facil
patient
might
discharg
viral
rna
undetect
respiratori
specimen
studi
warrant
ascertain
whether
patient
shed
live
viru
viral
cultur
prolong
rtpcrposit
specimen
obtain
patient
concomit
seroposit
shed
virion
coat
host
antibodi
render
noninfecti
criterion
discontinu
transmissionbas
precaut
neg
rtqpcr
result
two
set
nasopharyng
throat
swab
specimen
current
studi
one
patient
complet
symptom
resolut
test
posit
day
neg
find
result
suggest
might
excret
low
level
despit
clinic
recoveri
thu
serial
viral
load
monitor
antibodi
respons
consid
make
decis
infect
control
measur
viral
load
seem
relat
invers
serum
antibodi
respons
studi
antibodi
profil
vital
time
request
serolog
assay
interpret
antibodi
test
result
serolog
diagnosi
import
patient
present
late
low
viral
load
detect
limit
rtpcr
assay
patient
rise
antibodi
titr
day
symptom
onset
collect
serial
serum
sampl
convalesc
phase
would
use
serum
igg
amount
rise
time
earlier
igm
comparison
find
studi
igm
igg
eia
patient
seroposit
igg
igm
day
day
hospit
admiss
higher
antinp
igg
antinp
igm
proport
patient
current
studi
also
earlier
igg
igm
seroconvers
howev
find
could
also
account
lower
sensit
igm
eia
warrant
investi
gation
patient
serum
antibodi
level
correl
clinic
sever
notabl
one
patient
sever
diseas
earli
antibodi
respons
day
symptom
onset
deceas
patient
infect
sarscov
develop
faster
peak
antispik
antibodi
respons
compar
patient
recov
subsequ
reduc
bcell
immun
impair
neutralis
abil
sarscov
macaqu
model
antispik
igg
stimul
pulmonari
proinflammatori
respons
caus
acut
lung
injuri
detriment
effect
antispik
igg
attribut
effect
woundheal
macrophag
mediat
via
receptor
find
show
correl
antibodi
level
detect
eia
viru
neutralis
titr
especi
import
design
vaccin
studi
use
convalesc
plasma
therapeut
monoclon
antibodi
could
improv
clinic
outcom
paradox
caus
immuno
patholog
damag
recipi
wholegenom
sequenc
pair
sampl
four
patient
success
show
differ
individu
pair
genom
sequenc
howev
singl
nucleotid
polymorph
shown
emerg
hospitalis
merscov
infect
use
target
sequenc
approach
studi
patient
sampl
obtain
longer
interv
could
inform
high
viral
load
throat
wash
saliva
copi
per
ml
sarscov
rna
report
patient
sar
chines
macaqu
model
sarscov
salivari
gland
duct
earli
target
sarscov
therefor
like
sourc
virion
found
patient
saliva
particularli
earli
infect
import
find
studi
use
posterior
oropharyng
saliva
brought
throatclear
manoeuvr
ascertain
tempor
viral
load
profil
posterior
oropharynx
meet
point
secret
come
posterior
nasopharynx
salivari
gland
respiratori
secret
swept
trachealbronchi
tree
test
saliva
could
show
viral
shed
salivari
gland
upper
lower
respiratori
tract
moreov
greater
patient
accept
posterior
oropharyng
saliva
sampl
nasopharyng
throat
swab
obtain
respiratori
specimen
per
patient
test
thu
tempor
viral
load
profil
analys
statist
unlik
previou
clinic
studi
viral
kinet
infect
highli
pathogen
betacoronavirus
studi
need
ascertain
whether
salivari
gland
infect
studi
sever
limit
first
could
includ
patient
viral
load
antibodi
titr
data
avail
everyday
limit
common
problem
studi
emerg
infect
sarscov
merscov
patient
enrol
allow
adjust
potenti
confound
factor
could
affect
viral
load
antibodi
respons
second
patient
enrol
chronic
medic
ill
higher
proport
report
larg
clinic
seri
although
lower
antirbd
igg
level
note
among
patient
comorbid
studi
warrant
patient
third
posterior
oropharyng
saliva
sampl
differenti
whether
viru
come
nasopharynx
secret
lower
respiratori
tract
thu
studi
indic
whether
predilect
upper
lower
respiratori
tract
moreov
patient
might
clear
throat
effect
cough
saliva
deep
throat
could
decreas
test
sensit
compar
nasopharyng
swab
particularli
patient
predomin
upper
respiratori
involv
mild
symptom
final
abundantli
express
intern
np
might
crossantigen
sarscov
amino
acid
homolog
occasion
amino
acid
homolog
thu
less
abundantli
express
surfac
spike
protein
rbd
specif
direct
target
neutralis
antibodi
use
guard
specif
dual
antibodi
assay
emerg
infect
mani
unknown
studi
shed
light
viral
kinet
antibodi
respons
patient
provid
scientif
evid
guid
infect
control
polici
therapeu
tic
virolog
immunolog
studi
need
understand
infect
infect
control
measur
review
rapidli
evolv
epidemiolog
kkwt
kyy
contribut
studi
design
data
collect
data
analysi
data
interpret
literatur
search
write
report
otyt
wsl
art
tcw
dcl
jmcc
tshc
dpll
cycc
vccc
jfwc
ifnh
contribut
patient
recruit
data
collect
clinic
manag
ccyy
jpc
llc
wmc
khc
jdi
ackn
rwsp
ctl
zc
hc
contribut
experi
data
collect
data
analysi
data
interpret
author
review
approv
final
version
report
declar
compet
interest
